The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumInsights - Bluebird bio (BLUE) keeps hitting its marks. The first Sickle Cell patient treated with LengiGlobin, bluebird’s one-time gene therapy product, is producing healthy red blood cells, … Continue Reading
Read nowInsights - Achillion Pharmaceuticals (ACHN) announced after the close on Tuesday a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, of Johnson & Johnson (JNJ), to develop … Continue Reading
Read nowResearch - It’s been almost 30 years since the U.S. FDA approved the first statin to lower cholesterol, and the class remains the go-to therapy for treating hypercholesterolemia.
PremiumResearch - Following meetings with the U.S. FDA and Europe’s EMA, bluebird bio (BLUE) has clarity on the regulatory path for LentiGlobin BB305 in beta-thalassemia major. For … Continue Reading
PremiumRecap - Last week’s biotech recap covered the release of briefing documents from Vertex Pharmaceuticals’ (VRTX) advisory panel, which took place this Tuesday. The FDA’s Pulmonary-Allergy Drugs Advisory Committee voted … Continue Reading
Read nowInsights - Sorrento Therapeutics (SRNE) has sold lead drug candidate Cynviloq to NantPharma, founded by healthcare entrepreneur & SRNE’s largest investor, Patrick Soon-Shiong, and a subsidiary of partner NantWorks. Sorrento … Continue Reading
Read nowResearch - Initial data from the upcoming ASCO annual meeting (American Society of Clinical Oncology annual meeting) dropped last night when abstracts were released at 5:00 PM … Continue Reading
Read now
